Sort

Search

01/06/2024 Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy
Saccà, F, Salort-Campana, E, Jacob, S, Cortés-Vicente, E, Schneider-Gold, C. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. EUROPEAN JOURNAL OF NEUROLOGY. 2024; 31(6)DOI:10.1111/ene.16180. PMID:38117543. IF:3.900(Q1/3D).
01/06/2024 Novel patient-derived 2D and 3D muscle models in inclusion body myositis
Andújar-Sánchez, F, Cantó-Santos, J, Fernández-Garibay, X, Valls-Roca, L, Tobías, E, Guitart-Mampel, M, García-García, FJ, Laudo, B, Vilaseca-Capel, A, Padrosa, J, Moreno-Lozano, PJ, Grau-Junyent, JM, Matas, A, Gallardo, E, Fernández-Costa, J, Ramón-Azcón, J, Milisenda, JC, Garrabou, G. Novel patient-derived 2D and 3D muscle models in inclusion body myositis. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024 Cardiometabolic sex-specific response to a natural polysaccharide in individuals with obesity
Villaplana, VDS, Muñoz, N, Puntes, M, Badimón, L, Padró, T. Cardiometabolic sex-specific response to a natural polysaccharide in individuals with obesity. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024 Childhood adversity modulates structural brain changes in borderline personality but not in major depression disorder
Camacho-Téllez, V, Castro, MN, Wainsztein, AE, Goldberg, X, De Pino, G, Costanzo, EY, Cardoner, N, Menchón, JM, Soriano-Mas, C, Guinjoan, SM, Villarreal, MF. Childhood adversity modulates structural brain changes in borderline personality but not in major depression disorder. PSYCHIATRY RESEARCH-NEUROIMAGING. 2024; 340DOI:10.1016/j.pscychresns.2024.111803. PMID:38460393. IF:2.100(Q1/1D).
01/06/2024 Trait anxiety is associated with attentional brain networks
De la Peña-Arteaga, V, Chavarría-Elizondo, P, Juaneda-Seguí, A, Martínez-Zalacaín, I, Morgado, P, Menchón, JM, Picó-Pérez, M, Fullana, MA, Soriano-Mas, C. Trait anxiety is associated with attentional brain networks. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024; 83DOI:10.1016/j.euroneuro.2024.02.013. PMID:38492550. IF:6.700(Q1/1D).
01/06/2024 NRN1 epistasis with BDNF and CACNA1C: mediation effects on symptom severity through neuroanatomical changes in schizophrenia
Almodóvar-Payá, C, Guardiola-Ripoll, M, Giralt-López, M, Oscoz-Irurozqui, M, Canales-Rodríguez, EJ, Madre, M, Soler-Vidal, J, Ramiro, N, Callado, LF, Arias, B, Gallego, C, Pomarol-Clotet, E, Fatjó-Vilas, M. NRN1 epistasis with BDNF and CACNA1C: mediation effects on symptom severity through neuroanatomical changes in schizophrenia. Brain Structure & Function. 2024; 229(5)DOI:10.1007/s00429-024-02793-5. PMID:38720004. IF:2.900(Q1/1D).
01/06/2024 Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS
Chatterjee, M, Özdemir, S, Fritz, C, Möbius, W, Kleineidam, L, Mandelkow, E, Biernat, J, Dogdu, C, Peters, O, Cosma, NC, Wang, X, Schneider, LS, Priller, J, Spruth, E, Kühn, AA, Krause, P, Klockgether, T, Vogt, IR, Kimmich, O, Spottke, A, Hoffmann, DC, Fliessbach, K, Miklitz, C, McCormick, C, Weydt, P, Falkenburger, B, Brandt, M, Guenther, R, Dinter, E, Wiltfang, J, Hansen, N, Bähr, M, Zerr, I, Flöel, A, Nestor, PJ, Düzel, E, Glanz, W, Incesoy, E, Bürger, K, Janowitz, D, Perneczky, R, Rauchmann, BS, Hopfner, F, Wagemann, O, Levin, J, Teipel, S, Kilimann, I, Goerss, D, Prudlo, J, Gasser, T, Brockmann, K, Mengel, D, Zimmermann, M, Synofzik, M, Wilke, C, Selma-Gonzáalez, J, Turon-Sans, J, Santos-Santos, MA, Alcolea, D, Rubio-Guerra, S, Fortea, J, Carbayo, A, Lleó, A, Rojas-García, R, Illán-Gala, I, Wagner, M, Frommann, I, Roeske, S, Bertram, L, Heneka, MT, Brosseron, F, Ramirez, A, Schmid, M, Beschorner, R, Halle, A, Herms, J, Neumann, M, Barthélemy, NR, Bateman, RJ, Rizzu, P, Heutink, P, Dols-Icardo, O, Höglinger, G, Hermann, A, Schneider, A. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. NATURE MEDICINE. 2024; 30(6)DOI:10.1038/s41591-024-02937-4. PMID:38890531. IF:50.000(Q1/1D).
01/06/2024 Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis
Fortea, J, Alvarado-Tapias, E, Simbrunner, B, Ezcurra, I, Hernández-Gea, V, Aracil, CF, Herrera, EL, Puente, A, Roig, C, Reiberger, T, García-Pagán, JC, Panero, JLC, Mandorfer, M, Villanueva, C, Crespo, J. Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis. JOURNAL OF HEPATOLOGY. 2024; 80DOI:. PMID:. IF:33.000(Q1/1D).